The FDA approved the combination of relacorilant and nab-paclitaxel in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The FDA has approved relacorilant (Lifyorli) plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results